Payment overview · 2025
General Payments
$372.19
28 reported records · 9 companies
Healthcare provider profile · identity verified
Nicolas Thomas, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PARIS, IL · NPI 1235892431
Verified facts
What the public records show
CMS Open Payments records show Nicolas Thomas, APRN received $372.19 in general payments during 2025 across 28 reported records.
GlaxoSmithKline, LLC. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Otezla, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $144.71 | 38.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.48 | 12.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.42 | 12.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.43 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.61 | 9.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.91 | 5.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.63 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.41 | 3.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.59 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $372.19 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $103.36 | 9 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $41.35 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.35 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 605 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 354 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 98 |
| Lisinopril | Lisinopril | 215 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 84 |
| Alprazolam | Alprazolam | 178 | 56 |
| Omeprazole | Omeprazole | 178 | 70 |
| Furosemide | Furosemide | 168 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 70 |
| Ozempic | Semaglutide | 145 | 54 |
| Gabapentin | Gabapentin | 144 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 62 |
| Losartan Potassium | Losartan Potassium | 118 | 56 |
| Metformin Hcl | Metformin Hcl | 112 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 38 |
| Carvedilol | Carvedilol | 111 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 25 |
| Potassium Chloride | Potassium Chloride | 89 | 41 |
| Montelukast Sodium | Montelukast Sodium | 87 | 33 |
| Tramadol Hcl | Tramadol Hcl | 86 | 27 |
| Azithromycin | Azithromycin | 78 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 25 |
| Trazodone Hcl | Trazodone Hcl | 78 | 27 |
| Eliquis | Apixaban | 77 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 38 |
| Simvastatin | Simvastatin | 77 | 32 |
| Famotidine | Famotidine | 76 | 22 |
| Lorazepam | Lorazepam | 76 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 17 |
| Meloxicam | Meloxicam | 75 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 21 |
| Methylprednisolone | Methylprednisolone | 72 | 55 |
| Donepezil Hcl | Donepezil Hcl | 71 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 34 |
| Mirtazapine | Mirtazapine | 70 | 11 |
| Bumetanide | Bumetanide | 65 | 17 |
| Allopurinol | Allopurinol | 64 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 26 |
| Clonidine | Clonidine | 51 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 18 |
| Clonazepam | Clonazepam | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 45 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 15 |
| Prednisone | Prednisone | 39 | 25 |
| Ibuprofen | Ibuprofen | 38 | 21 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 18 |
| Memantine Hcl | Memantine Hcl | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | 14 |
| Topiramate | Topiramate | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Cephalexin | Cephalexin | 33 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | 13 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | 15 |
| Fenofibrate | Fenofibrate,micronized | 25 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Amoxicillin | Amoxicillin | 24 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Atenolol | Atenolol | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 20 | 12 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $372.19 · 28 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, FANAPT, FARXIGA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error